After dropping its only clinical-stage candidate last month, ADC Therapeutics is shutting down a U.K. research site and laying off 30% of its workforce. The Swiss biopharma is also discontinuing early development for some preclinical programs in solid tumors, including exatecan-based antibody-drug conjugates targeting Claudin-6 and ASCT2. Source: Fierce Biotech 12/6/2025